Olema Pharmaceuticals (OLMA) Amortization of Deferred Charges (2022 - 2026)

Olema Pharmaceuticals (OLMA) has 5 years of Amortization of Deferred Charges data on file, last reported at $301000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 4.88% year-over-year to $301000.0 in Q1 2026; TTM through Mar 2026 was $1.2 million, a 3.57% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 2.26% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $301000.0, roughly flat from $301000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for OLMA reached as high as $327000.0 in Q3 2022 and fell as low as $287000.0 in Q2 2024.
• Historically, Amortization of Deferred Charges has averaged $307352.9 across 5 years, with a median of $301000.0 in 2025.
• Across the five-year window, Amortization of Deferred Charges declined 11.96% in 2024 and gained 4.88% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $326000.0 in 2022, then fell by 0.61% to $324000.0 in 2023, then retreated by 11.42% to $287000.0 in 2024, then grew by 4.88% to $301000.0 in 2025, then changed by 0.0% to $301000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $301000.0 in Q1 2026, $301000.0 in Q4 2025, and $300000.0 in Q3 2025.